Ridgetech Inc.
No enriched coverage for $RDGT in the last 7 days.
No SEC Form 4 filings for $RDGT in the last 30 days.
Ridgetech, Inc. (Nasdaq: RDGT) reported fiscal year 2026 results for the year ended March 31, 2026. Revenue rose 10.2% to $132.16 million, driven by a full year of Allright’s online platform after its Feb. 28, 2025 acquisition. Gross profit increased 23.8% to $4.75 million, but net loss was $1.25 million versus net income $10.20 million a year earlier.
Ridgetech, Inc. (Nasdaq: RDGT) said its wholly owned Zhejiang Jiuxin Medicine Co. was elected a vice-president unit of the Hangzhou Qiantang District Biomedical and Cosmetic High-Quality Development Association, to be inaugurated July 28, 2026. The company links the role to Jiuxin’s full-variety drug traceability code scanning in Zhejiang, following an March 2026 inspection by the Zhejiang Medical Products Administration.
Biotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).
Recent RDGT coverage spans insider activity, earnings and corporate actions.
Wholesale transition and Allright contribution drove revenue growth, but margins remain thin and the company swung to a net loss.
Recognition of Jiuxin Medicine’s traceability initiative may support Ridgetech’s compliance and operational positioning, but it is not a quantified financial catalyst.
The rally is likely technical and sentiment-driven around reverse-split aftermath and upcoming earnings.
The filing is a disclosed insider/large-owner buy, but it is small in absolute terms and lacks a stated catalyst.
The filing is a fresh insider/large-owner buy, but it is not a fundamental catalyst like earnings, guidance, or a deal.
alphai scores every news story that mentions RDGT with an AI model for sentiment and relevance, and aggregates insider trades from Ridgetech Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ridgetech, Inc. (Nasdaq: RDGT) reported fiscal year 2026 results for the year ended March 31, 2026. Revenue rose 10.2% to $132.16 million, driven by a full year of Allright’s online platform after its Feb. 28, 2025 acquisition. Gross profit increased 23.8% to $4.75 million, but net loss was $1.25 million versus net income $10.20 million a year earlier.
6 min readRidgetech, Inc. (Nasdaq: RDGT) said its wholly owned Zhejiang Jiuxin Medicine Co. was elected a vice-president unit of the Hangzhou Qiantang District Biomedical and Cosmetic High-Quality Development Association, to be inaugurated July 28, 2026. The company links the role to Jiuxin’s full-variety drug traceability code scanning in Zhejiang, following an March 2026 inspection by the Zhejiang Medical Products Administration.
3 min readBiotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).
6 min readHRT FINANCIAL LP purchased 41,136 shares of Ridgetech Inc. (RDGT) at an average of $1.52 ($1.50–$1.52) across 2 trades over 2026-06-30 to 2026-07-01.
2 min readHRT FINANCIAL LP purchased 19,373 shares of Ridgetech Inc. (RDGT) at $1.61 on 2026-06-11.
2 min readHRT FINANCIAL LP purchased 39,336 shares of Ridgetech Inc. (RDGT) at an average of $1.72 ($1.62–$1.78) across 2 trades over 2026-06-09 to 2026-06-10.
1 min read
